# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-25-019697
Filing Date
2025-10-27
Accepted
2025-10-27 13:26:15
Documents
17
Period of Report
2025-10-27

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | formdef14a.htm iXBRL | DEF 14A | 968706
2 | GRAPHIC | formdef14a_001.jpg | GRAPHIC | 344694
3 | GRAPHIC | formdef14a_002.jpg | GRAPHIC | 237364
| Complete submission text file | 0001493152-25-019697.txt |  | 3209334

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
4 | XBRL SCHEMA FILE | lixt-20241231.xsd | EX-101.SCH | 6111
5 | XBRL DEFINITION FILE | lixt-20241231_def.xml | EX-101.DEF | 11006
6 | XBRL LABEL FILE | lixt-20241231_lab.xml | EX-101.LAB | 61993
7 | XBRL PRESENTATION FILE | lixt-20241231_pre.xml | EX-101.PRE | 46078
19 | EXTRACTED XBRL INSTANCE DOCUMENT | formdef14a_htm.xml | XML | 163152

Mailing Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432
Business Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39717 | Film No.: 251418888
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)